Flood David, Zhang Yuan S, Nichols Emma, Li Chihua, Zaninotto Paola, Langa Kenneth M, Lee Jinkook, Manne-Goehler Jennifer
Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.
BMJ Open Diabetes Res Care. 2025 Mar 18;13(2):e004678. doi: 10.1136/bmjdrc-2024-004678.
There is a need for comparable worldwide data on the impact of diabetes on mortality. This study assessed diabetes and all-cause mortality among middle-aged and older adults in five countries.
We analyzed adults aged 51 years or older followed between 2010 and 2020 from population-based cohorts from China, England, Mexico, rural South Africa, and the USA. The cohorts are part of an international network of longitudinal aging studies with similar sampling designs, eligibility, and assessment methods. Diabetes was defined by self-report or an elevated diabetes blood-based biomarker meeting the clinical criteria for diabetes. All-cause mortality was assessed through linkages or informant interviews. We used Poisson regression models to estimate mortality rate ratios and mortality rate differences, comparing people with diabetes to those without diabetes. Models were adjusted for age, gender, education, smoking status, body mass index, economic status, and, in South Africa, HIV status.
We included 29 397 individuals, of whom 4916 (16.7%) died during the study period. The median follow-up time ranged from 4.6 years in South Africa to 8.3 years in China. The adjusted all-cause mortality rate ratios for people with diabetes versus those without diabetes ranged from 1.53 (95% CI: 1.39 to 1.68) in the USA to 2.02 (95% CI: 1.34 to 3.06) in Mexico. The adjusted mortality rate differences (per 1000 person-years) for people with diabetes vers those without diabetes ranged from 11.9 (95% CI: 4.8 to 18.9) in England to 24.6 (95% CI: 12.2 to 37.0) in South Africa.
Diabetes was associated with increased all-cause mortality in population-based cohorts in China, England, Mexico, rural South Africa, and the USA. Limitations included differences in diabetes biomarkers and selection criteria across cohorts. The results highlight the urgent need to implement clinical and public health interventions worldwide to reduce excess diabetes mortality.
需要有关于糖尿病对死亡率影响的全球可比数据。本研究评估了五个国家中老年人的糖尿病情况和全因死亡率。
我们分析了来自中国、英格兰、墨西哥、南非农村和美国基于人群队列中年龄在51岁及以上且在2010年至2020年期间接受随访的成年人。这些队列是具有相似抽样设计、入选标准和评估方法的国际纵向衰老研究网络的一部分。糖尿病通过自我报告或符合糖尿病临床标准的基于血液的糖尿病生物标志物升高来定义。通过关联或知情人访谈评估全因死亡率。我们使用泊松回归模型来估计死亡率比和死亡率差异,将糖尿病患者与非糖尿病患者进行比较。模型针对年龄、性别、教育程度、吸烟状况、体重指数、经济状况进行了调整,在南非还针对艾滋病毒感染状况进行了调整。
我们纳入了29397名个体,其中4916人(16.7%)在研究期间死亡。中位随访时间从南非的4.6年到中国的8.3年不等。糖尿病患者与非糖尿病患者调整后的全因死亡率比在美国为1.53(95%置信区间:1.39至1.68),在墨西哥为2.02(95%置信区间:1.34至3.06)。糖尿病患者与非糖尿病患者调整后的死亡率差异(每1000人年)在英格兰为11.9(95%置信区间:4.8至18.9),在南非为24.6(95%置信区间:12.2至37.0)。
在中国、英格兰、墨西哥、南非农村和美国基于人群的队列中,糖尿病与全因死亡率增加相关。局限性包括各队列中糖尿病生物标志物和选择标准的差异。结果凸显了在全球范围内实施临床和公共卫生干预措施以降低糖尿病超额死亡率的迫切需求。